TechSeeker Profile

Celgene Corporation
Profile last edited on: 10/14/2016

Hematology Oncology Product Development and Sales
TS Type
N/A
Status
N/A
Year Founded
1986
Last Involved Year
2019

Key People / Management

  Mark J Alles -- President

  Robert J Hugin -- President

  Michel Attal -- Business Development

Location Information

86 Morris Avenue
Summit, NJ 07901
   (908) 673-9000
   www.celgene.com

Public Profile

Spun out as independent company from the Celanese Corporation when the latter merged with American Hoechset in 1986, Celgene Corporation is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Products marketed include REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh├žet's disease, atopic dermatitis, and ulcerative colitis. The company?s products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum;

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
7,000
Revenue
$5.7M
Public/Private
Publicly Traded
Stock Info
NASDAQ : CELG
Received SBIR $$
No

Techseeker firm in the news